Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details Narrative)

v3.19.3
Significant Accounting Policies (Details Narrative)
3 Months Ended 9 Months Ended
Jul. 25, 2019
USD ($)
Sep. 30, 2019
USD ($)
Breathalyzers
shares
Sep. 30, 2018
USD ($)
Breathalyzers
shares
Sep. 30, 2019
USD ($)
Breathalyzers
shares
Sep. 30, 2018
USD ($)
Breathalyzers
shares
Dec. 31, 2018
USD ($)
Restricted cash   $ 115,094   $ 115,094   $ 500,000
Maturities of securities       less than one year    
Unrealized gain on securities   45,597   $ 45,597    
Unrealized loss on securities   1,805 $ 6,900 1,805 $ (5,543)  
Marketable securities gain (loss)   6,416 (6,900) 2,155 (11,300)  
Proceeds from sale of marketable securities   1,201,870 3,153,987 2,556,516 5,460,662  
Allowances for doubtful accounts for trade receivables   458,902   458,902   606,835
Bad debt expenses   1,078 0 5,325 125,500  
Allowance for doubtful accounts, charged off   148,024        
Trade receivables   230,900   230,900   176,326
Trade payable, current   505,048   505,048   686,578
Depreciation expense   9,541 17,366 24,516 44,716  
Intangible assets, net   213,405   213,405   243,411
Amortization expense   10,001 42,777 30,006 128,331  
Accrued liabilities   0   0   23,179
Rebates recognized during period   6,220 26,262 $ 22,597 70,156  
Income tax examination, likelihood percentage       The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.    
Unrecognized tax benefits      
Income tax benefit    
Accrued for penalties and interest        
Product cost of sales   285,510 476,453 751,311 1,076,779  
Cost of net revenue   10,990 18,126 38,479 83,063  
Net loss attributable to common shareholders   $ 837,026 $ 3,083,950 $ 2,548,875 $ 7,011,394  
Weighted average basic and diluted common shares outstanding | shares   12,512,709 11,779,584 12,499,055 10,805,151  
Shipping and Handling [Member]            
Product cost of sales   $ 8,567 $ 8,625 $ 30,564 $ 41,006  
Patents, Trademarks and Customer Lists [Member]            
Intangible assets, net   3,897,635   3,897,635   3,897,635
Intangible assets, accumulated amortization   $ 3,684,230   $ 3,684,230   $ 3,654,224
Sales Revenue, Net [Member]            
Concentration risk percentage   92.00% 95.00% 81.00% 72.00%  
Concentration risk, number of customer | Breathalyzers   2 3 2 2  
Sales Revenue, Net [Member] | Customer One [Member]            
Concentration risk percentage   57.00% 61.00% 47.00% 55.00%  
Sales Revenue, Net [Member] | Customer Two [Member]            
Concentration risk percentage   35.00% 18.00% 34.00% 17.00%  
Sales Revenue, Net [Member] | Customer Three [Member]            
Concentration risk percentage     16.00%      
Trade Receivable [Member]            
Concentration risk percentage       97.00%    
Concentration risk, number of customer | Breathalyzers       3    
Trade Receivable [Member] | Customer One [Member]            
Concentration risk percentage       66.00%    
Trade receivables   $ 458,902   $ 458,902    
Trade Receivable [Member] | Customer Two [Member]            
Concentration risk percentage       17.00%    
Trade receivables   114,538   $ 114,538    
Trade Receivable [Member] | Customer Three [Member]            
Concentration risk percentage       14.00%    
Trade receivables   $ 97,908   $ 97,908    
Cost of Goods [Member]            
Concentration risk percentage   50.00% 54.00%      
Concentration risk, number of supplier | Breathalyzers   2 3      
Cost of Goods [Member] | Supplier One [Member]            
Concentration risk percentage   28.00% 25.00% 44.00%    
Concentration risk, number of supplier | Breathalyzers       1    
Cost of Goods [Member] | Supplier Two [Member]            
Concentration risk percentage   22.00% 18.00%      
Cost of Goods [Member] | Supplier Three [Member]            
Concentration risk percentage     11.00%      
Trade Payables [Member] | Two Vendors [Member]            
Concentration risk percentage       68.00%    
Concentration risk, number of supplier | Breathalyzers       2    
Trade Payables [Member] | Vendor One [Member]            
Trade payable, current   $ 200,913   $ 200,913    
Trade Payables [Member] | Vendor Two [Member]            
Trade payable, current   45,785   45,785    
Administrative Expenses [Member]            
Deposit reserve made   $ 100,000   $ 100,000    
Unsecured Promissory Note [Member]            
Advances to related party $ 100,000          
Maturity date Oct. 02, 2019          
Minimum [Member]            
Normal credit terms extended to customers       30 days    
Minimum [Member] | Cost of Goods [Member] | One Supplier [Member]            
Concentration risk percentage         14.00%  
Concentration risk, number of supplier | Breathalyzers         1  
Maximum [Member]            
Normal credit terms extended to customers       90 days